The current financial score of Rallybio Corp is 6.62. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 117.01%.
The current valuation score of Rallybio Corp is 9.10. Its current P/E ratio is -11.53, which is -97.98% below the recent high of -0.23 and -31.24% above the recent low of -15.13.
No earnings forecast score is currently available for Rallybio Corp. The Biotechnology & Medical Research industry's average is 8.12. The average price target is 8.00, with a high of 8.00 and a low of 8.00.
The current price momentum score of Rallybio Corp is 2.77. Currently, the stock price is trading between the resistance level at 16.58 and the support level at 15.07, making it suitable for range-bound swing trading.
The current institutional shareholding score of Rallybio Corp is 5.00. The latest institutional shareholding proportion is 65.82%, representing a quarter-over-quarter decrease of 1.97%.
The current risk assessment score of Rallybio Corp is 4.64. The company's beta value is -0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.